Regulatory strategy is a core commercial competency in biotechnology — the choice of regulatory pathway, the design of clinical trials, the selection of endpoints, and the management of FDA interactions can accelerate or delay drug approval by years and determine the commercial opportunity window. FDA Breakthrough Therapy Designation, Accelerated Approval, Priority Review, and Fast Track designations collectively affect the development timelines of a majority of new biotechnology drug approvals. The FDA's accelerated approval reform — restricting the use of surrogate endpoints and requiring confirmatory trials to be underway at the time of approval — is reshaping clinical development strategy across oncology and rare disease.
Topics Covered
• FDA Accelerated Approval Reform
• Breakthrough Therapy Designation
• Orphan Drug Regulatory Framework
• Global Regulatory Pathways — EMA, PMDA, NMPA
• Biosimilar Regulatory Requirements
• Cell and Gene Therapy Regulation
• Real-World Evidence in Regulatory Submissions
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. FDA Accelerated Approval Reform
4. Breakthrough Therapy Designation
5. Orphan Drug Regulatory Framework
6. Global Regulatory Pathways — EMA, PMDA, NMPA
7. Biosimilar Regulatory Requirements
8. Cell and Gene Therapy Regulation
9. Real-World Evidence in Regulatory Submissions
10. Competitive Landscape
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. FDA Accelerated Approval Reform
Table 3. Breakthrough Therapy Designation
Table 4. Orphan Drug Regulatory Framework
Table 5. Global Regulatory Pathways
Table 6. Biosimilar Regulatory Requirements
Table 7. Cell and Gene Therapy Regulation
Table 8. Real-World Evidence in Regulatory Submissions
Table 9. Competitive Landscape
Table 10. Leading Companies — Technology Investment and Strategy 2025
Table 11. M&A and Partnership Activity 2023-2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
Amgen
Gilead Sciences
Regeneron
Biogen
Vertex
BioNTech
Moderna
Genentech
CSL Behring
